公开(公告)号：US20170239205A1

公开(公告)日：2017-08-24

申请号：US15455006

申请日：2017-03-09

Applicant: Baylor Research Institute

Inventor： Charles R. ROE

IPC: A61K31/225 ,  A23L33/115 ,  A23L33/16 ,  A61K9/00

CPC classification number: A61K31/225 ,  A23K20/158 ,  A23K20/174 ,  A23K50/10 ,  A23K50/75 ,  A23K50/80 ,  A23L2/52 ,  A23L33/10 ,  A23L33/115 ,  A23L33/12 ,  A23L33/16 ,  A23L33/175 ,  A23V2002/00 ,  A61K9/0053 ,  A61K9/0095 ,  A61K31/19 ,  A61K31/20 ,  A61K31/202 ,  A61K31/22 ,  A61K31/23 ,  A61K38/47 ,  C12Y302/0102

Abstract: A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.

公开(公告)号：US20160296485A1

公开(公告)日：2016-10-13

申请号：US15188095

申请日：2016-06-21

Applicant: Baylor Research Institute

Inventor： Charles R. ROE

IPC: A61K31/20

CPC classification number: A61K31/20 ,  A61K31/19 ,  A61K31/194 ,  A61K31/23

Abstract: A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial β-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof.

Abstract translation: 已经发现治疗需要治疗心脏病症的患者的方法包括向患者施用七碳脂肪酸化合物或其衍生物，其中所述化合物或其衍生物能够容易地进入线粒体而没有特殊的转运酶。 已经发现适合于治疗心脏或外科手术患者心脏组织的膳食制剂包括七碳脂肪酸链，其中七碳脂肪酸链的特征在于通过运输机制横向内线粒体膜的能力 其不需要肉碱棕榈酰转移酶I，肉碱棕榈酰转移酶II或肉碱/酰基肉毒碱转位酶和进行线粒体β-氧化的能力，并且其中所述化合物选自正庚酸或其衍生物，甘油三酯包含 正庚酸或其衍生物，三庚醇或其衍生物。

公开(公告)号：US20130123359A1

公开(公告)日：2013-05-16

申请号：US13722020

申请日：2012-12-20

Applicant: Baylor Research Institute

Inventor： Charles R. ROE

IPC: A61K31/20 ,  A61K31/19

CPC classification number: A61K31/20 ,  A23K20/158 ,  A23L33/12 ,  A23L33/40 ,  A61K31/19 ,  A61K31/202 ,  A61K31/22 ,  A61K31/225 ,  A61K31/23

Abstract: According to the present invention, acquired metabolic derangements or fatty acid disorders in humans that are manifested by a deficiency in at least one enzyme involved in fatty acid metabolism are treated with a five carbon or a fifteen carbon fatty acid source. Rapid nutritional supplementation can also be provided to a mammalian cell by providing either a five carbon or fifteen carbon fatty acid source. Dietary formulations suitable for human consumption comprising either a five carbon fatty acid, a fifteen carbon fatty acid or triglycerides thereof is also disclosed.

Abstract translation: 根据本发明，用五碳或十五碳脂肪酸源处理由脂肪酸代谢中涉及的至少一种酶的缺陷所表现的人类中获得的代谢紊乱或脂肪酸紊乱。 还可以通过提供五碳或十五碳脂肪酸源向哺乳动物细胞提供快速营养补充。 还公开了适合于人类消费的膳食制剂，其包含五碳脂肪酸，十五碳脂肪酸或其甘油三酸酯。